Alembic announces USFDA tentative approval for Selexipag for Injection, 1,800 mcg/vial
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
This product will be manufactured at Lupin’s Pithampur facility in India
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Glenmark released Picture Post Cards on World Vitiligo Day
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Subscribe To Our Newsletter & Stay Updated